Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 19, 2024
Product Development
Tertiary lymphoid structures: Key to predicting and improving cancer immunotherapy response?
At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Oct 10, 2024
Discovery & Translation
Baker and DeepMind Nobel: Two sides of a computational protein coin
Protein design updates its engine: The field’s shift from physical models to deep learning
BioCentury | May 31, 2024
Distillery Therapeutics
Armored, iPSC-derived CAR macrophages for pancreatic cancer
BioCentury | May 3, 2024
Discovery & Translation
CAR T cells: Cancer, autoimmunity, and beyond?
ASGCT abstracts highlight applications for CAR Ts outside of cancer
BioCentury | May 2, 2024
Data Byte
FDA approved five NMEs in April
Day One, X4 and ImmunityBio each received their first drug approvals
BioCentury | Apr 5, 2024
Finance
Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal
Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
BioCentury | Mar 20, 2024
Emerging Company Profile
Reverb: redirecting endogenous cytokines to tumors
Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue
BioCentury | Jan 9, 2024
Deals
Jan. 8 Quick Takes: Novartis taps China-based Argo for RNAi deal
Plus: Venrock unveils $650M fund and more from Calypso, Isomorphic, Bayer, Flagship and Vertex
BioCentury | Dec 22, 2023
Discovery & Translation
Move over oncology — I&I will write the next big stories in innovation
Biotech execs, investors eye immunology and inflammation, plus neurology as innovation drivers, but precision medicine still to prove itself: a BioCentury survey
Items per page:
1 - 10 of 200